Artículo
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina
Fecha de publicación:
08/2018
Editorial:
Nature Publishing Group
Revista:
Nature Reviews Gastroenterology & Hepatology
ISSN:
1759-5045
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.
Palabras clave:
NASH
,
NAFLD
,
BIOMARKERS
,
OMICS
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IDIM)
Articulos de INST.DE INVEST.MEDICAS
Articulos de INST.DE INVEST.MEDICAS
Citación
Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina; Noninvasive biomarkers in NAFLD and NASH — current progress and future promise; Nature Publishing Group; Nature Reviews Gastroenterology & Hepatology; 15; 8; 8-2018; 461-478
Compartir
Altmétricas